A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of recMAGE+A3+AS15 Antigen-Specific Cancer Immunotherapeutic As Adjuvant Therapy in Patients with Resectable MAGE-A3-positive Non-Small Cell Lung Cancer

Grants and Contracts Details

StatusFinished
Effective start/end date5/1/10 → 4/30/12

Funding

  • GlaxoSmithKline: $3,500.00